Zhejiang Shengda Bio-Pharm Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Bin Zhou

Amministratore delegato

CN¥921.2k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	5.2yrs
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

Oct 28

What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Aug 08

Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Jun 12

Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Apr 25

Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 08

AMMINISTRATORE DELEGATO

Bin Zhou (58 yo)

5.2yrs

Mandato

CN¥921,200

Compensazione

Mr. Bin Zhou serves as GM & Director of Zhejiang Shengda Bio-Pharm Co., Ltd. since September 19, 2019.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Bin Zhou	GM & Director	5.2yrs	CN¥921.20k	Nessun dato
Jing Zhu	Deputy GM & Director	4.9yrs	CN¥294.00k	Nessun dato
Jianxin Xu	Deputy GM	10.9yrs	CN¥401.90k	Nessun dato
Yongquan Li	Independent Director	3.2yrs	CN¥80.00k	Nessun dato
Han Xu	Chairman of the Supervisory Board	2.5yrs	Nessun dato	Nessun dato
Bufei Chen	Director	10.9yrs	Nessun dato	Nessun dato
Xiqin Chen	Independent Director	4.9yrs	CN¥80.00k	Nessun dato
Cancan Hong	Supervisor	2.6yrs	Nessun dato	0.00059% CN¥ 15.3k
Yong Gang Zhu	Director	2.5yrs	Nessun dato	Nessun dato

4.9yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 603079 sono considerati esperti (durata media dell'incarico 4.9 anni).

Zhejiang Shengda Bio-Pharm Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Shengda Bio-Pharm Co., Ltd., Annual General Meeting, May 10, 2024

Less than half of directors are independent

Recent updates

Subdued Growth No Barrier To Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) With Shares Advancing 28%

Third quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.011 in 3Q 2023)

Zhejiang Shengda Bio-Pharm Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: EPS: CN¥0.091 (vs CN¥0.069 loss in 2Q 2023)

What Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 27% Share Price Gain Is Not Telling You

Zhejiang Shengda Bio-Pharm Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Revenues Working Against Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) Share Price Following 26% Dive

Zhejiang Shengda Bio-Pharm Co., Ltd.'s (SHSE:603079) 30% Dip In Price Shows Sentiment Is Matching Revenues

Zhejiang Shengda Bio-Pharm Co., Ltd., Annual General Meeting, May 10, 2024

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.02 in 1Q 2023)

Zhejiang Shengda Bio-Pharm Co., Ltd. to Report Q1, 2024 Results on Apr 20, 2024

New major risk - Share price stability

Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) Surges 31% Yet Its Low P/S Is No Reason For Excitement

New minor risk - Share price stability

Zhejiang Shengda Bio-Pharm Co., Ltd. to Report Fiscal Year 2023 Results on Apr 20, 2024

Second quarter 2023 earnings released: CN¥0.069 loss per share (vs CN¥0.11 profit in 2Q 2022)

Zhejiang Shengda Bio-Pharm Co., Ltd. (SHSE:603079) announces an Equity Buyback for CNY 34 million worth of its shares.

Full year 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.44 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.037 (vs CN¥0.091 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.11 (vs CN¥0.14 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 1Q 2021)

Third quarter 2021 earnings released: EPS CN¥0.091 (vs CN¥0.29 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.52 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.38 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.17 (vs CN¥0.30 in FY 2019)

New 90-day low: CN¥20.73

New 90-day low: CN¥20.92

New 90-day low: CN¥24.13

New 90-day low: CN¥24.46

New 90-day low: CN¥26.37

Third quarter earnings released

Zhejiang Shengda Bio-Pharm Co., Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥26.80

New 90-day low - CN¥27.05

First half earnings released